Intravenous Fish Oil Monotherapy as a Source of Calories and Fatty Acids Promotes Age-Appropriate Growth in Pediatric Patients with Intestinal Failure-Associated Liver Disease
Intravenous Fish Oil Monotherapy as a Source of Calories and Fatty Acids Promotes Age-Appropriate Growth in Pediatric Patients with Intestinal Failure-Associated Liver Disease
复制标题
DOI：
10.1016/j.jpeds.2019.12.065
复制
发表时间：
2020-04-01
影响因子：
5.1
通讯作者：
Puder, Mark
中科院分区：
文献类型：
--
作者：
Gura, Kathleen;Premkumar, Muralidhar H.;Puder, Mark
目的比较接受鱼油静脉注射脂肪乳剂（FOLE）和接受大豆油静脉注射脂肪乳剂（SOLE.Study design）的肠衰竭相关性肝病（IFALD）儿童的生长情况。研究受试者接受开放标签FOLE（1 g/kg/天），直至IFALD消退或停止肠外营养。历史对照受试者接受SOLE（高达3 g/kg/天）。生长指标（体重，身高/身长，头围的变化），前白蛋白，甘油三酯，和葡萄糖进行了比较，随着时间的推移，使用Wilcoxon秩和test.Results虽然在所有的生长指标的变化是相似的两组（P > 0.05），FOLE收件人表现出整体改善的生长轨迹。28周后，FOLE受体的平均体重在-1至1的z评分范围内，表明年龄适当的生长。FOLE收件人一贯有较高的前白蛋白，较低的甘油三酯，随着时间的推移，更多的正常血糖浓度与SOLE recipients.Conclusions儿童IFALD谁收到FOLE有类似的增长和代谢异常较少的SOLE相比。
Objective To compare growth in children with intestinal failure-associated liver disease (IFALD) who received a fish oil intravenous lipid emulsion (FOLE) to those who received a soybean oil intravenous lipid emulsion (SOLE).Study design This multisite, retrospective study pair-matched FOLE (n = 82) to SOLE recipients (n = 41) using baseline serum direct bilirubin levels and postmenstrual age. Study subjects received open-label FOLE (1 g/kg/ day) until IFALD resolved or parenteral nutrition was stopped. Historical control subjects received SOLE (up to 3 g/kg/day). Growth measures (changes in body weight, height/length, and head circumference), prealbumin, triglycerides, and glucose were compared between groups over time using the Wilcoxon rank-sum test.Results Although changes in all of the growth measures were similar for both groups (P > .05), FOLE recipients demonstrated an overall improved growth trajectory. After 28 weeks, FOLE recipients had a mean body weight within a z score range of -1 to 1 indicating age-appropriate growth. FOLE recipients consistently had higher prealbumin, lower triglyceride, and more normal glucose concentrations over time compared with SOLE recipients.Conclusions Children with IFALD who received FOLE had similar growth and fewer metabolic abnormalities compared with those who received SOLE.